No Detail Found!

Immunohistochemical expression of human epidermal growth factor receptor-2 (HER-2) in common salivary gland carcinomas

Author(s)
Zunaira Saeed Department of Histopathology, Oral and Maxillofacial Pathology, Armed Forces Institute of Pathology,Rawalpindi, Pakistan
Nadeem Zafar Department of Histopathology, Oral and Maxillofacial Pathology, Armed Forces Institute of Pathology,Rawalpindi, Pakistan
Nighat Ara Army Medical College (NUMS),Rawalpindi, Pakistan
Saadia Muneer Army Medical College (NUMS),Rawalpindi, Pakistan
Zainab Asif Department of Histopathology, Oral and Maxillofacial Pathology, Armed Forces Institute of Pathology,Rawalpindi, Pakistan
Azka Haroon Department of Histopathology, Oral and Maxillofacial Pathology, Armed Forces Institute of Pathology,Rawalpindi, Pakistan
Zahra Saeed CMH Medical College and Institute of Dentistry,(NUMS) Lahore-, Pakistan
Abstract
Background: Carcinomas of the salivary gland are known to be aggressive in nature, making them difficult to manage. The therapeutic options offered include excision of the gland (maxillectomy in cases of palatal tumours), with or without lymph node dissection, proceeded with radiotherapy. Chemotherapy has not produced promising outcomes and has a minimal impact as a therapeutic alternative. Targeted therapy against human epidermal growth factor receptor 2 (HER-2), which is a commonly used treatment modality for their mammary analogues, is not being offered to these patients since scant literature is available showing its usefulness and no promising evidence is present regarding their efficacy and efficiency in such cases. The study aimed to evaluate and quantify the immunohistochemical expression of HER-2 in cases of adenoid cystic carcinoma (AdCC), mucoepidermoid carcinoma (MEC) and salivary duct carcinoma (SDC), which are analogues of similar tumours arising in breast tissue. Methods: A retrospective, cross-sectional study was carried out in the department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, duration of which was six months. A total of 45 cases (15 of each tumour) were taken, and sampled using non-probability convenience technique. The immunohistochemical marker, monoclonal HER-2 antibody (Leica microsystem Germany) was applied on appropriate blocks of all included cases. The staining pattern and intensity were recorded after visualizing the slides under a light microscope. Results: Seven cases of salivary duct carcinoma and a single case of mucoepidermoid carcinoma expressed positivity for HER-2, while no expression could be seen in the case of adenoid cystic carcinoma. A statistically significant difference was seen when HER-2 expression was compared among the aforementioned tumours. Conclusion: The use of targeted therapy against HER-2 is limited to patients of salivary duct carcinoma and a fraction of patients suffering from mucoepidermoid carcinoma.
Publication Details
Page(s) 280-284
Published Journal: Journal of Ayub Medical College, Volume: 35, Issue: 2, Year: 2023

Request the full text from PASTIC

Keywords
Mucoepidermoid carcinoma, Salivary gland, Adenoid cystic carcinoma, Human epidermal growth factor receptor Immunohistochemistry, Salivary duct carcinoma
0

Citations

0

Downloads

34

Views